---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-248461"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2023-10-02T23:59:59+00:00"
generated_at: "2026-06-10T06:20:03.894396+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aadi appoints Dave Lennon as President and CEO; base salary $640K, option for 490K shares

## Summary
- David J. Lennon appointed President and CEO, effective Oct 2, 2023; Scott Giacobello returns to CFO role.
- Compensation: $640,000 base salary, up to 60% annual bonus, $240,000 sign-on (cash + RSUs), option for 490,000 shares.
- Board increased from 8 to 9; Lennon appointed as Class II director. Company adopted 2023 Inducement Plan reserving 600,000 shares.
- Press release highlights Lennon’s Novartis background and FYARRO pipeline expansion into endometrial, neuroendocrine cancers.

## SEC filing metadata
- accession: 0001193125-23-248461
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2023-10-02T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000119312523248461/0001193125-23-248461-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000119312523248461/d561858d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-248461
- JSON: https://secwatch.observer/filing/0001193125-23-248461.json
- Plain text: https://secwatch.observer/filing/0001193125-23-248461.txt

## Key facts
- Executive change
  David J. Lennon was appointed as President and Chief Executive Officer at Whitehawk Therapeutics, Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: the Board of Directors (the “ Board ”) of Aadi Bioscience, Inc. (the “ Company ”) appointed David J. Lennon, Ph.D., to serve as the Company’s President and Chief Executive Officer and principal executive officer, effective as of October 2, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000119312523248461/0001193125-23-248461-index.htm
- Executive change
  Scott Giacobello changed role as Chief Financial Officer at Whitehawk Therapeutics, Inc..
  - Action: continued
  - Role: Chief Financial Officer
  source text: Mr. Giacobello has served as the Company’s Interim CEO and President and principal executive officer since March 15, 2023, and will continue to serve as the Company’s Chief Financial Officer, a position he has held since November 2021, following Dr. Lennon’s appointment.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000119312523248461/0001193125-23-248461-index.htm
- Executive change
  David J. Lennon was appointed as Class II Director at Whitehawk Therapeutics, Inc..
  - Action: appointed
  - Role: Class II Director
  source text: the Board increased the Board’s size from eight (8) to nine (9) directors and appointed Dr. Lennon to fill the resulting vacancy
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000119312523248461/0001193125-23-248461-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.